Cadre Holdings Inc Revenue Growth Rates (CDRE), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cadre Holdings inc   (NYSE: CDRE)
 

CDRE's Revenue Growth by Quarter and Year

Cadre Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CDRE/growth
https://api.csimarket.com/api/v1/companies/CDRE/fundamentals
https://api.csimarket.com/api/v1/companies/CDRE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CDRE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 202.88
2nd Quarter June 207.13
1st Quarter March 155.17
FY 565.18

CDREs Annual Revenue
Cadre Holdings Inc 's Revenue in the fiscal year 2025 $ 609.63 millions
Cadre Holdings Inc 's Revenue in the fiscal year 2024 $ 567.48 millions
Cadre Holdings Inc 's Revenue in the fiscal year 2023 $ 481.73 millions
Cadre Holdings Inc 's Revenue in the fiscal year 2022 $ 457.84 millions
Cadre Holdings Inc 's Revenue in the fiscal year 2021 $ 427.29 millions




CDRE Revenue third quarter 2026 Y/Y Growth Comment
Cadre Holdings inc achieved in the third quarter 2026, above Company average Revenue growth of 30.36% year on year, to $ 202.88 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue growth. While Cadre Holdings Inc ' s Revenue rise of 30.36% ranks overall at the positon no. 706 in the third quarter 2026.


CDRE Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 30.36 %
2nd Quarter June 32.56 %
1st Quarter March 20.17 %
FY   -

Financial Statements
Cadre Holdings Inc 's third quarter 2026 Revenue $ 202.88 millions CDRE's Income Statement
Cadre Holdings Inc 's third quarter 2025 Revenue $ 155.63 millions Quarterly CDRE's Income Statement


CDRE Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.05 %
2nd Quarter June 33.49 %
1st Quarter March -7.98 %
FY (Year on Year)   -


Back to CDRE Growth rate Comparisons >> Back to CDRE Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #158
Overall #706

Revenue Y/Y Growth Statistics
High Average Low
42.75 % 7.23 % -65.36 %
(Sep 30 2025)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #41
Healthcare Sector #158
Overall #706
Revenue Y/Y Growth Statistics
High Average Low
42.75 % 7.23 % -65.36 %
(Sep 30 2025)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Cadre Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
182.69 % 9.36 % -63.02 %
(Dec 31 2020)  


CDRE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Cadre Holdings Inc disclosed fall in Revenue from the second quarter by -2.05% to $ 202.88 millions, from $ 207.13 millions achived in the previous reporting period.

But that's not important problem, as Cadre Holdings Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Cadre Holdings Inc 's Revenue growth quarter on quarter, overall rank is 340.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #79
Overall #340
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #19
Healthcare Sector #79
Overall #340
Revenue Q/Q Growth Statistics
High Average Low
182.69 % 9.36 % -63.02 %
(Dec 31 2020)  


CDRE's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Cadre Holdings Inc disclosed fall in Revenue from the second quarter by -2.05% to $ 202.88 millions, from $ 207.13 millions achived in the previous reporting period.

But that's not important problem, as Cadre Holdings Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Cadre Holdings Inc 's Revenue growth quarter on quarter, overall rank is 340.


Cadre Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 686.54
Y / Y Revenue Growth (TTM) 20.37 %
Year on Year Revenue Growth Overall Ranking # 1791
Seqeuential Revenue Change (TTM) 8 %
Seq. Revenue Growth (TTM) Overall Ranking # 2765


Cumulative Revenue growth Comment
With 20.37% annual Revenue growth, Cadre Holdings Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 280 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 705 to 1791.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 145
Healthcare Sector # 281
Overall # 1791

Revenue TTM Y/Y Growth Statistics
High Average Low
20.37 %
 6.29 %
-32.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 145
Sector # 390
S&P 500 # 2765
Cumulative Revenue growth Comment
With 20.37% annual Revenue growth, Cadre Holdings Inc would report a record annual Revenue rise if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 280 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 705 to 1791.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 145
Healthcare Sector # 281
Overall # 1791

Revenue TTM Y/Y Growth Statistics
High Average Low
20.37 %
6.29 %
-32.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 145
Sector # 390
S&P 500 # 2765




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CDRE's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions


About Cadre Holdings Inc Revenue Growth Rates (CDRE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cadre Holdings Inc (CIK 1860543).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-122697
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cadre Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.